缬沙坦治疗原发性高血压对内源性纤溶活性的影响

Effects of valsartan on endogenous fibrinolytic activity in patients with essential hypertension

目的 :观察缬沙坦治疗原发性高血压 (EH)的同时对内源性纤溶活性的影响。方法 :用发色底物分解显色法测定 6 4例EH患者 (EH组 )和 35例正常对照者 (对照组 )的组织型纤溶酶原激活因子 (t PA)、纤溶酶原激活抑制物 (PAI 1)的活性 ,然后EH组口服缬沙坦 80mg ,每日 1次 ,共 8周 ,比较治疗前后的t PA和PAI 1活性变化。结果 :EH组治疗前t PA活性较对照组明显降低 ,PAI 1活性明显升高 (P <0 .0 5 )。经缬沙坦治疗 8周后 ,t PA活性较治疗前显著上升 ,PAI 1活性降低 (P <0 .0 5 )。结论 :缬沙坦在降低血压的同时 ,有改善内源性纤溶活性的作用。

Objective:The aims of this study were to observe the influence of valsartan on endogenous fibrinolytic activity.Method: The activity of t PA (tissue plasminogen activator) and PAI 1 (plasminogen activator inhibitor I) were measured in 64 patients with essential hypertension and 35 normal controls by a photometric method. Sixty four patients were treated with valsartan (80mg every day) for 8 weeks.Result: Compared with control group, hypertensive patients had significanthy lower activity of t PA (P< 0.01 ) and significantly higher activity of PAI 1 (P< 0.05 ). While after treatment with valsartan for 8 weeks, the activety of t PA was significantly elevated (P< 0.01 ) and the activity of PAI 1 was decreased (P< 0.05 ).Conclusion: Blood pressure lowering therapy with valsartan can significantly improve endogenous fibrinolytic activity.